title: Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?
abstract: BACKGROUND
  Withdrawal of the drug(s) that cause severe cutaneous adverse reactions is usually recommended without proof that it alters the course of those reactions.
  
  
  OBJECTIVE
  To determine whether the timing of causative drug withdrawal is related to the prognosis of patients with toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS).
  
  
  METHODS
  A 10-year observational study (January 1, 1987, through October 30, 1997) of patients admitted to a dermatological intensive care unit, using binary logistic regression analysis.
  
  
  METHODS
  A single referral unit in a university hospital.
  
  
  METHODS
  Consecutive sample of 203 patients with TEN or SJS. Exclusion criteria included causative drug undetermined, lack of information on disease evolution, the date of causative drug(s) withdrawal, or the date when the first definite sign of TEN or SJS appeared.
  
  
  METHODS
  Death before hospital discharge.
  
  
  RESULTS
  One hundred thirteen patients were included; 74 had TEN and 39 had SJS; 20 died. The drug causing TEN or SJS was withdrawn early in 64 patients and late (after the first definite sign of TEN or SJS) in 49 patients. After adjustment for confounding variables (age, maximum extent of detachment, admission year, human immunodeficiency virus status), our model showed that the earlier the causative drug was withdrawn, the better the prognosis (odds ratio, 0.69 for each day; 95% confidence interval, 0.53-0.89). Patients exposed to causative drugs with long half-lives had an increased risk of dying (odds ratio, 4.9; 95% confidence interval, 1.3-18.9). The variables did not interact.
  
  
  CONCLUSIONS
  Prompt withdrawal of drug(s) that are suspected to cause SJS or TEN may decrease mortality. Prompt withdrawal of causative drugs should be a priority when blisters or erosions appear in the course of a drug eruption.
authors.affiliation: Department of Dermatology, Hospital Provincial de Pontevedra, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Garcia-Doval
authors.forename: L
authors.initials: L
authors.lastname: LeCleach
authors.forename: H
authors.initials: H
authors.lastname: Bocquet
authors.forename: X L
authors.initials: XL
authors.lastname: Otero
authors.forename: J C
authors.initials: JC
authors.lastname: Roujeau
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006207:Half-Life; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D011379:Prognosis; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000209:etiology* / Q000401:mortality*; D013997:Time Factors
chemical_list: D004364:Pharmaceutical Preparations